Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026

Core Viewpoint - Palvella Therapeutics, Inc. is set to report its full year 2025 financial results on March 31, 2026, and will host a conference call for investors to discuss these results and provide a corporate update [1]. Company Overview - Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare skin diseases and vascular malformations that lack FDA-approved treatments [3]. - The company is developing a pipeline of product candidates based on its patented QTORIN™ platform, with a focus on lifelong conditions [3]. - Palvella's lead product candidate is QTORIN™ 3.9% rapamycin anhydrous gel, aimed at treating microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas [3]. - The second product candidate, QTORIN™ pitavastatin, is being developed for disseminated superficial actinic porokeratosis [3]. Regulatory Status - Both QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and have not received FDA approval or approval from any other regulatory agency [4].